AURINIA PHARMACEUTICALS INC.

(AUPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aurinia Announces Positive Topline Results from the Aurora 2 Continuation Study of Lupkynis™ (Voclosporin) for the Treatment of Adults with Active Lupus Nephritis (Ln)

12/09/2021 | 06:15am EDT

Aurinia Pharmaceuticals Inc. announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious complication in patients with systemic lupus erythematosus (SLE). In combination with background immunosuppressive therapy, LUPKYNIS is the first and only FDA-approved medicine with three years of pivotal trial results, including long-term safety data, within LN. Aurinia also announced the initiation of ENLIGHT-LN, a U.S.-based prospective, observational registry of adult patients with LN treated with LUPKYNIS. The registry is intended to support the interests of patients, clinicians, regulatory bodies, payers and industry by obtaining longitudinal data on LUPKYNIS. The Company aims to initiate approximately 75 sites across the U.S. Additional details regarding this registry will be provided in 2022.


© S&P Capital IQ 2021
All news about AURINIA PHARMACEUTICALS INC.
05:46aAUPH ALERT : The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in th..
PR
05/23Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 Euro..
AQ
05/20AURINIA PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders, Financ..
AQ
05/20Aurinia Pharmaceuticals Says Kidney Inflammation Treatment Continuation Study Shows Saf..
MT
05/20Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 Euro..
BU
05/20Aurinia Pharmaceuticals Inc. Presents Results from the Two-Year Aurora 2 Continuation S..
CI
05/20VOCLOSPORIN FOR LUPUS NEPHRITIS : Results of the Two-year AURORA 2 Continuation Study
PU
05/17TRANSCRIPT : Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call
CI
05/17AUPH ALERT : The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in th..
PR
05/16Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 E..
BU
More news
Analyst Recommendations on AURINIA PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2022 137 M - -
Net income 2022 -102 M - -
Net cash 2022 363 M - -
P/E ratio 2022 -16,6x
Yield 2022 -
Capitalization 1 678 M 1 678 M -
EV / Sales 2022 9,60x
EV / Sales 2023 5,29x
Nbr of Employees 300
Free-Float 93,7%
Chart AURINIA PHARMACEUTICALS INC.
Duration : Period :
Aurinia Pharmaceuticals Inc. Technical Analysis Chart | AUPH | CA05156V1022 | MarketScreener
Technical analysis trends AURINIA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 11,84 $
Average target price 23,81 $
Spread / Average Target 101%
EPS Revisions
Managers and Directors
Peter S. Greenleaf President, Chief Executive Officer & Director
Joseph M. Miller Chief Financial Officer
George M. Milne Chairman
Robert B. Huizinga Executive Vice President-Research
Neil Solomons Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AURINIA PHARMACEUTICALS INC.-48.23%1 678
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666